Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSIW) Current Assets (2022 - 2025)

TriSalus Life Sciences' Current Assets history spans 4 years, with the latest figure at $32.2 million for Q4 2025.

  • For Q4 2025, Current Assets rose 56.0% year-over-year to $32.2 million; the TTM value through Dec 2025 reached $32.2 million, up 56.0%, while the annual FY2025 figure was $32.2 million, 56.0% up from the prior year.
  • Current Assets reached $32.2 million in Q4 2025 per TLSIW's latest filing, down from $33.3 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $38.1 million in Q2 2025 to a low of $161454.0 in Q2 2023.
  • Average Current Assets over 4 years is $17.7 million, with a median of $20.8 million recorded in 2023.
  • Peak YoY movement for Current Assets: tumbled 39.4% in 2023, then skyrocketed 17205.86% in 2024.
  • A 4-year view of Current Assets shows it stood at $17.2 million in 2022, then increased by 21.19% to $20.9 million in 2023, then decreased by 0.93% to $20.7 million in 2024, then skyrocketed by 56.0% to $32.2 million in 2025.
  • Per Business Quant, the three most recent readings for TLSIW's Current Assets are $32.2 million (Q4 2025), $33.3 million (Q3 2025), and $38.1 million (Q2 2025).